Cytokine-release hypersensitivity reaction after the first dose of benralizumab for severe eosinophilic asthma

Ann Allergy Asthma Immunol. 2021 Dec;127(6):701-702. doi: 10.1016/j.anai.2021.08.006. Epub 2021 Aug 13.

Authors

Dan Morgenstern-Kaplan¹, Estefania Vasquez-Echeverri², Ismael Carrillo-Martin¹, Sergio E Chiarella³, Alexei Gonzalez-Estrada⁴

Affiliations

¹ Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida.
² Allergy Department, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
³ Division of Allergic Diseases, Mayo Clinic, Rochester, Minnesota.
⁴ Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, Florida. Electronic address: gonzalez.alexei@mayo.edu.

PMID: 34391900
DOI: 10.1016/j.anai.2021.08.006

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Anti-Asthmatic Agents* / adverse effects
Antibodies, Monoclonal, Humanized* / adverse effects
Asthma* / drug therapy
Cytokines
Eosinophils
Female
Humans
Pulmonary Eosinophilia* / drug therapy

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Cytokines
benralizumab